SA
GALT icon

Sovran Advisors’s Galectin Therapeutics GALT Stock Holding History

Sovran Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$875K Buy
257,997
+167
+0.1% +$433 0.07% 279
2026
Q1 		$585K Buy
257,830
+31,956
+14% +$97.2K 0.05% 328
2025
Q4 		$712K Buy
225,874
+68,469
+43% +$361K 0.06% 285
2025
Q3 		$798K Sell
157,405
-31,567
-17% -$119K 0.07% 251
2025
Q2 		$395K Sell
188,972
-10,858
-5% -$16.2K 0.04% 351
2025
Q1 		$276K Buy
199,830
+13,816
+7% +$19.4K 0.04% 389
2024
Q4 		$214K Buy
+186,014
New +$446K 0.03% 396

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sovran Advisors's GALT Position: Q2 2026 in Review

Sovran Advisors increased its Galectin Therapeutics (GALT) stake by 0.06% in Q2 2026, buying an estimated $433 and bringing the position to 257,997 shares worth $875K. The position accounts for 0.07% of the portfolio, ranked #279.

Sovran Advisors first reported a position in GALT in Q4 2024 and has held it in 7 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Sovran Advisors held 257,997 shares of Galectin Therapeutics worth $875K as of Q2 2026.
  • Sovran Advisors bought 167 Galectin Therapeutics shares in Q2 2026, an estimated $433.
  • Galectin Therapeutics made up 0.07% of Sovran Advisors's portfolio in Q2 2026, its #279 holding.
  • Sovran Advisors first reported a position in Galectin Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.